Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (cancelled)

2. (presently amended) A method for the prevention or treatment of asthma, bronchitis, interstitial lung disease, insulin resistance, prediabetes, type 2 diabetes mellitus, metabolic syndrome or hypertension combined with hyperlipidaemia or atherosclerosis in a mammal comprising administering a pharmaceutical composition comprising telmisartan or one of the salts thereof and atorvastatin.

3. to 6. (cancelled)

7. (previously presented) The method according to claim 2, wherein the mammal is a human.

8. (previously presented) The method according to claim 2, wherein a fasting blood sugar level of the mammal exceeds 110 mg of glucose per dl of plasma.

9. (previously presented) The method according to claim 2, wherein a blood level for triglyceride of the mammal exceeds 150 mg/dl.

10. (original) The method according to claim 7, wherein a blood level for high-density lipoprotein in the human is less than 40 mg per dl of plasma in a female human and less than 50 mg per dl of plasma in a male human.

11. (previously presented) The method according to claim 2, wherein the systolic blood pressure of the mammal exceeds a value of 130 mm Hg and the diastolic blood pressure of the mammal exceeds a value of 80 mm Hg.

12. (previously presented) The method according to claim 10, wherein the atorvastatin or a polymorph or salt thereof is administered orally in a daily dose of about 0.018 mg/kg body

weight to 6.43 mg/kg body weight and the telmisartan or salt thereof is administered orally in a daily dose of about 0.143 mg/kg to 7.143 mg/kg body weight.

13. (previously presented) The method according to claim 10, wherein the atorvastatin or a polymorph or salt thereof is administered parenterally in a daily dose of about 0.286 mg/kg body weight and the telmisartan or salt thereof is administered parenterally in a daily dose of about 0.286 mg/kg body weight.

14. (previously presented) A pharmaceutical composition, comprising telmisartan and atorvastatin, optionally with one or more excipients.

15. (original) The pharmaceutical composition according to claim 14, wherein the formulation of the pharmaceutical composition comprises 20-200 mg telmisartan and 2.5-40 mg atorvastatin.

16. (previously presented) The pharmaceutical composition according to claim 15, wherein a ratio of atorvastatin to telmisartan or salt thereof is 1:2 to 1:8 (wt/wt).

17. (original) The pharmaceutical composition according to claim 14, further comprising a diuretic.

18. (original) The pharmaceutical composition according to claim 17, wherein the diuretic consists of 10-50 mg of hydrochlorothiazide or 10-50 mg of chlorthalidone.